Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.

Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K; REGAIN Study Group.

J Neurol Sci. 2019 Aug 3;407:116419. doi: 10.1016/j.jns.2019.08.004. [Epub ahead of print]

2.

The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement.

Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, Takahashi T, Uzawa A, Uchida T, Masuda H, Ohtani R, Nomura K, Hiwasa T, Kuwabara S.

J Neuroimmunol. 2019 Nov 15;336:577021. doi: 10.1016/j.jneuroim.2019.577021. Epub 2019 Aug 21.

PMID:
31473520
3.

Response to "Letter to the editors in regard to the article 'Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis'".

Kanai T, Uzawa A, Kuwabara S.

J Neurol Sci. 2019 Sep 15;404:157-158. doi: 10.1016/j.jns.2019.07.020. Epub 2019 Jul 31. No abstract available.

PMID:
31398695
4.

Frequency and features of myasthenia gravis developing after thymectomy.

Uzawa A, Kanai T, Oda F, Ozawa Y, Yasuda M, Kawaguchi N, Himuro K, Yoshino I, Kuwabara S.

Eur J Neurol. 2019 Jul 25. doi: 10.1111/ene.14052. [Epub ahead of print]

PMID:
31347231
5.

Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.

Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, Kuwabara S, Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J, Ogino M, Nishiyama K, Nomura K, Yokota T.

Eur J Neurol. 2019 Jul 15. doi: 10.1111/ene.14039. [Epub ahead of print]

PMID:
31309642
6.

Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.

Masuda H, Mori M, Hirano S, Kojima K, Uzawa A, Uchida T, Ohtani R, Kuwabara S.

J Neurol Sci. 2019 Aug 15;403:78-84. doi: 10.1016/j.jns.2019.06.011. Epub 2019 Jun 10.

PMID:
31233973
7.

[Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].

Uzawa A, Kuwabara S.

Brain Nerve. 2019 Jun;71(6):565-570. doi: 10.11477/mf.1416201317. Review. Japanese.

PMID:
31171753
8.

Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.

Ozawa Y, Uzawa A, Kanai T, Oda F, Yasuda M, Kawaguchi N, Himuro K, Kuwabara S.

J Neurol Sci. 2019 Jul 15;402:12-15. doi: 10.1016/j.jns.2019.05.003. Epub 2019 May 7.

PMID:
31100651
9.

[Fc Fusion Protein as a Novel Treatment for Myasthenia Gravis].

Uzawa A, Yamashita J, Kuwabara S.

Brain Nerve. 2019 May;71(5):525-530. doi: 10.11477/mf.1416201306. Japanese.

PMID:
31089000
10.

Response to "regarding the article 'Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis'".

Kanai T, Uzawa A, Kuwabara S.

J Neurol Sci. 2019 Apr 15;399:229. doi: 10.1016/j.jns.2019.02.011. Epub 2019 Feb 11. No abstract available.

PMID:
30777369
11.

Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis.

Kanai T, Uzawa A, Kawaguchi N, Oda F, Ozawa Y, Himuro K, Kuwabara S.

J Neurol Sci. 2019 Jan 15;396:8-11. doi: 10.1016/j.jns.2018.10.018. Epub 2018 Oct 19.

PMID:
30391823
12.

Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.

Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, Kuwabara S.

Mult Scler. 2018 Oct 26:1352458518808473. doi: 10.1177/1352458518808473. [Epub ahead of print] No abstract available.

PMID:
30362874
13.

Antimetastatic Effects of Carbon-Ion Beams on Malignant Melanomas.

Matsumoto Y, Furusawa Y, Uzawa A, Hirayama R, Koike S, Ando K, Tsuboi K, Sakurai H.

Radiat Res. 2018 Oct;190(4):412-423. doi: 10.1667/RR15075.1. Epub 2018 Jul 24.

PMID:
30040045
14.

Spinal myoclonus selectively affecting the platysma after cervical laminectomy.

Uzawa A, Furuya T, Ohtori S, Kuwabara S.

Neurology. 2018 Jul 3;91(1):45-46. doi: 10.1212/WNL.0000000000005746. No abstract available.

PMID:
29967202
15.

MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis.

Uzawa A, Mori M, Kuwabara S.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):900. doi: 10.1136/jnnp-2018-318231. Epub 2018 Jun 6. No abstract available. Erratum in: J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):e4.

PMID:
29875185
16.

Case of convulsive seizure developing during electroretinographic recordings: a case report.

Hayashi Y, Miura G, Uzawa A, Baba T, Yamamoto S.

BMC Neurol. 2018 Apr 25;18(1):52. doi: 10.1186/s12883-018-1051-2.

17.

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, Kuwabara S.

J Neurol. 2018 May;265(5):1145-1150. doi: 10.1007/s00415-018-8813-z. Epub 2018 Mar 12.

PMID:
29532286
18.

Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines.

Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Kuwabara S.

Clin Exp Immunol. 2018 Jul;193(1):47-54. doi: 10.1111/cei.13123. Epub 2018 Mar 26.

19.

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

Ohtani R, Mori M, Uchida T, Uzawa A, Masuda H, Liu J, Kuwabara S.

Mult Scler J Exp Transl Clin. 2018 Feb 20;4(1):2055217318759692. doi: 10.1177/2055217318759692. eCollection 2018 Jan-Mar.

20.

Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction.

Wang H, Zhang XM, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kimura R, Mine S, Kamitsukasa I, Wada T, Aotsuka A, Yoshida Y, Kobayashi E, Matsutani T, Iwadate Y, Sugimoto K, Mori M, Uzawa A, Muto M, Kuwabara S, Takemoto M, Kobayashi K, Kawamura H, Ishibashi R, Yokote K, Ohno M, Chen PM, Nishi E, Ono K, Kimura T, Machida T, Takizawa H, Kashiwado K, Shimada H, Ito M, Goto KI, Iwase K, Ashino H, Taira A, Arita E, Takiguchi M, Hiwasa T.

Oncotarget. 2017 Dec 31;9(5):5600-5613. doi: 10.18632/oncotarget.23789. eCollection 2018 Jan 19.

21.

Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder.

Masuda H, Mori M, Uzawa A, Uchida T, Ohtani R, Kobayashi S, Kuwabara S.

J Neurol Sci. 2018 Feb 15;385:64-68. doi: 10.1016/j.jns.2017.11.041. Epub 2017 Dec 22.

PMID:
29406915
22.

Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.

Masuda H, Mori M, Umehara K, Furihata T, Uchida T, Uzawa A, Kuwabara S.

J Neuroimmunol. 2018 Mar 15;316:117-120. doi: 10.1016/j.jneuroim.2018.01.001. Epub 2018 Jan 3.

PMID:
29329699
23.

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.

Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, Suzuki Y, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Akaishi T, Aoki M.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):513-517. doi: 10.1136/jnnp-2017-316625. Epub 2017 Nov 24.

24.

A clinical predictive score for postoperative myasthenic crisis.

Kanai T, Uzawa A, Sato Y, Suzuki S, Kawaguchi N, Himuro K, Oda F, Ozawa Y, Nakahara J, Suzuki N, Takahashi YK, Ishibashi S, Yokota T, Ogawa T, Yokoyama K, Hattori N, Izaki S, Oji S, Nomura K, Kaneko J, Nishiyama K, Yoshino I, Kuwabara S.

Ann Neurol. 2017 Nov;82(5):841-849. doi: 10.1002/ana.25087. Epub 2017 Nov 10.

PMID:
29083502
25.

Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder.

Masuda H, Hirano S, Takahashi N, Hatsugano E, Uzawa A, Uchida T, Ohtani R, Kuwabara S, Mori M.

PLoS One. 2017 Aug 28;12(8):e0184012. doi: 10.1371/journal.pone.0184012. eCollection 2017.

26.

Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder.

Mori M, Uzawa A, Kuwabara S.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):620. doi: 10.1136/jnnp-2017-315769. Epub 2017 Jun 12. No abstract available.

PMID:
28607119
27.

Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.

Muto M, Mori M, Liu J, Uzawa A, Uchida T, Masuda H, Ohtani R, Sugimoto K, Kuwabara S.

J Neuroimmunol. 2017 Apr 15;305:131-134. doi: 10.1016/j.jneuroim.2017.02.008. Epub 2017 Feb 7.

PMID:
28284333
28.

Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.

Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S.

J Neuroimmunol. 2017 Apr 15;305:102-107. doi: 10.1016/j.jneuroim.2017.01.024. Epub 2017 Feb 4.

PMID:
28284329
29.

Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica.

Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Sawai S, Kuwabara S.

Clin Chim Acta. 2017 Jun;469:144-149. doi: 10.1016/j.cca.2017.03.006. Epub 2017 Mar 8.

PMID:
28283439
30.

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.

Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Kanai T, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K.

BMJ Open. 2017 Feb 23;7(2):e013278. doi: 10.1136/bmjopen-2016-013278.

31.

Adequate tacrolimus concentration for myasthenia gravis treatment.

Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, Kuwabara S.

Eur J Neurol. 2017 Feb;24(2):270-275. doi: 10.1111/ene.13189. Epub 2016 Nov 7.

PMID:
28102047
32.

Response to treatment of myasthenia gravis according to clinical subtype.

Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Nagane Y, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M, Utsugisawa K.

BMC Neurol. 2016 Nov 17;16(1):225.

33.

Metformin enhances the radiosensitivity of human liver cancer cells to γ-rays and carbon ion beams.

Kim EH, Kim MS, Furusawa Y, Uzawa A, Han S, Jung WG, Sai S.

Oncotarget. 2016 Dec 6;7(49):80568-80578. doi: 10.18632/oncotarget.12966.

34.

Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.

Uchida T, Mori M, Uzawa A, Masuda H, Muto M, Ohtani R, Kuwabara S.

Mult Scler. 2017 Jul;23(8):1072-1084. doi: 10.1177/1352458516672015. Epub 2016 Sep 28.

PMID:
27682231
35.

A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells.

Homma M, Uzawa A, Tanaka H, Kawaguchi N, Kanai T, Nakajima K, Narita M, Hara Y, Maruyama H, Ogawa Y, Himuro K, Kuwabara S.

Neurotherapeutics. 2017 Jan;14(1):191-198. doi: 10.1007/s13311-016-0476-9.

36.

Early fast-acting treatment strategy against generalized myasthenia gravis.

Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M.

Muscle Nerve. 2017 Jun;55(6):794-801. doi: 10.1002/mus.25397. Epub 2017 Feb 3.

37.

Neuroimmunology of a natural disaster.

Kuwabara S, Uzawa A, Mori M.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):283. doi: 10.1136/jnnp-2016-314198. Epub 2016 Aug 19. No abstract available.

PMID:
27543200
38.

Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis.

Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Ohtani R, Akiba R, Yokouchi H, Yamamoto S, Kuwabara S.

J Neurol Sci. 2016 Aug 15;367:375-9. doi: 10.1016/j.jns.2016.06.036. Epub 2016 Jun 17.

PMID:
27423624
39.

Progressive Multifocal Leukoencephalopathy Localized in the Cerebellum and Brainstem Associated with Idiopathic CD4(+) T Lymphocytopenia.

Aotsuka Y, Uzawa A, Nishimura K, Kojima K, Yamaguchi M, Makino T, Nakamichi K, Saijo M, Kuwabara S.

Intern Med. 2016;55(12):1645-7. doi: 10.2169/internalmedicine.55.6649. Epub 2016 Jun 15.

40.

Changes in inflammatory cytokine networks in myasthenia gravis.

Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S.

Sci Rep. 2016 May 13;6:25886. doi: 10.1038/srep25886.

41.

HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients.

Kanai T, Uzawa A, Kawaguchi N, Sakamaki T, Yoshiyama Y, Himuro K, Oda F, Kuwabara S.

J Neurol Sci. 2016 Apr 15;363:116-8. doi: 10.1016/j.jns.2016.02.031. Epub 2016 Feb 16.

PMID:
27000234
42.

Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis.

Uzawa A, Mori M, Uchida T, Masuda H, Ohtani R, Kuwabara S.

Clin Chim Acta. 2016 Jan 30;453:131-3. doi: 10.1016/j.cca.2015.12.013. Epub 2015 Dec 11.

PMID:
26686775
43.

Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria.

Uzawa A, Mori M, Uchida T, Masuda H, Ohtani R, Kuwabara S.

Mult Scler. 2016 Sep;22(10):1371-5. doi: 10.1177/1352458515615954. Epub 2015 Nov 9.

PMID:
26552730
44.

Determination of the relative biological effectiveness and oxygen enhancement ratio for micronuclei formation using high-LET radiation in solid tumor cells: An in vitro and in vivo study.

Hirayama R, Uzawa A, Obara M, Takase N, Koda K, Ozaki M, Noguchi M, Matsumoto Y, Li H, Yamashita K, Koike S, Ando K, Shirai T, Matsufuji N, Furusawa Y.

Mutat Res Genet Toxicol Environ Mutagen. 2015 Nov;793:41-7. doi: 10.1016/j.mrgentox.2015.08.003. Epub 2015 Aug 14.

PMID:
26520371
45.

Evaluation of therapeutic gain for fractionated carbon-ion radiotherapy using the tumor growth delay and crypt survival assays.

Yoshida Y, Ando K, Ando K, Murata K, Yoshimoto Y, Musha A, Kubo N, Kawamura H, Koike S, Uzawa A, Takahashi T, Ohno T, Nakano T.

Radiother Oncol. 2015 Nov;117(2):351-7. doi: 10.1016/j.radonc.2015.09.027. Epub 2015 Oct 8.

PMID:
26454348
46.

Increased serum peroxiredoxin 5 levels in myasthenia gravis.

Uzawa A, Kawaguchi N, Kanai T, Himuro K, Oda F, Kuwabara S.

J Neuroimmunol. 2015 Oct 15;287:16-8. doi: 10.1016/j.jneuroim.2015.07.013. Epub 2015 Jul 29.

PMID:
26439955
47.

The Effect of p53 Status of Tumor Cells on Radiosensitivity of Irradiated Tumors With Carbon-Ion Beams Compared With γ-Rays or Reactor Neutron Beams.

Masunaga SI, Uzawa A, Hirayama R, Matsumoto Y, Sakurai Y, Tanaka H, Tano K, Sanada Y, Suzuki M, Maruhashi A, Ono K.

World J Oncol. 2015 Aug;6(4):398-409. doi: 10.14740/wjon941w. Epub 2015 Aug 27.

48.

Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis.

Sugiyama A, Mori M, Masuda H, Uchida T, Muto M, Uzawa A, Ito S, Kuwabara S.

J Neurol Sci. 2015 Aug 15;355(1-2):147-9. doi: 10.1016/j.jns.2015.06.004. Epub 2015 Jun 3.

PMID:
26055314
49.

Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.

Muto M, Mori M, Hiwasa T, Takiguchi M, Iwadate Y, Uzawa A, Uchida T, Masuda H, Sugimoto K, Kuwabara S.

J Neuroimmunol. 2015 Jul 15;284:30-6. doi: 10.1016/j.jneuroim.2015.05.005. Epub 2015 May 6.

PMID:
26025055
50.

Designing a ridge filter based on a mouse foot skin reaction to spread out Bragg-peaks for carbon-ion radiotherapy.

Uzawa A, Ando K, Kase Y, Hirayama R, Matsumoto Y, Matsufuji N, Koike S, Kobashi G.

Radiother Oncol. 2015 May;115(2):279-83. doi: 10.1016/j.radonc.2015.04.007. Epub 2015 May 13.

PMID:
25981129

Supplemental Content

Support Center